We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Atriva Therapeutics Secures Us Patent for Mek Inhibitor Zapnometinib (Atr-002)

RNA strand.
Credit: iStock.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Atriva Therapeutics, a leader in immunomodulatory and anti-viral therapies, is pleased to announce that it has been granted a US patent for its MEK inhibitor zapnometinib (ATR-002). The patent includes claims for the treatment of bacterial infections, the treatment of infections caused by any strain of influenza viruses (including bird flu H5N1), the use of ATR-002 in combination with neuraminidase inhibitors for the treatment of influenza virus infections and the use of ATR-002 for the treatment of co-infections involving influenza viruses and bacteria.

"This pertinent patent grant significantly strengthens Atriva`s patent portfolio and substantially increases its value as we are progressing zapnometinib into Phase 2 clinical development for patients hospitalized with a severe influenza infection”, said Christian Pangratz, Chief Executive Officer of Atriva Therapeutics.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

Zapnometinib is an oral, non-ATP-competitive, small-molecule inhibitor of MEK1/MEK2 with immunomodulatory and antiviral properties. Atriva is continuing the development of zapnometinib in severe viral diseases with epidemic or pandemic potential such as bird flu (H5N1). As a next step, the company is aiming to confirm the promising results from the Phase 2 proof-of-concept study “RESPIRE” – conducted with patients hospitalized with a moderate to severe SARS-CoV-2 infection – in a Phase 2 clinical trial with patients hospitalized with a severe influenza infection, potentially also caused by bird flu H5N1.

The RESPIRE trial was funded by Atriva Therapeutics, the German Federal Ministry of Education and Research and co-funded by the European Investment Bank.